Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Viswanatha

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Leukemia|July 8, 2023
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)Mark Gurney, Abhishek A Mangaonkar, Terra Lasho, et al.
Haematologica|June 23, 2022
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experienceAyalew Tefferi, Naseema Gangat, Mithun Shah, et al.
Blood Cancer Journal|September 22, 2023
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneityTalha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, et al.
British Journal of Haematology|March 18, 2020
Characteristics of patients with myelodysplastic syndrome with balanced translocationsMaansi Joshi, Patricia Greipp, Colleen Ball, et al.
British Journal of Haematology|March 5, 2025
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndromeYael Kusne, Talha Badar, Terra Lasho, et al.
Leukemia Research|August 29, 2022
Comparison between GATA2 and DDX41-mutated myeloid neoplasmsAhmad Nanaa, Rong He, David Viswanatha, et al.
American Journal of Clinical Pathology|June 6, 2018
Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?Hong Fang, Prashant Kapoor, Wilson I Gonsalves, et al.
Transplantation and Cellular Therapy|May 18, 2025
Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell TransplantAnmol Baranwal, Christopher Graham, Khalil Hassan, et al.
Blood Advances|October 13, 2021
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasmsHassan B Alkhateeb, Ahmad Nanaa, David Viswanatha, et al.
Blood Cancer Journal|April 9, 2023
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndromeAref Al-Kali, Ahmad Nanaa, David Viswanatha, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Leukemia|July 8, 2023
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)Mark Gurney, Abhishek A Mangaonkar, Terra Lasho, et al.
Haematologica|June 23, 2022
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experienceAyalew Tefferi, Naseema Gangat, Mithun Shah, et al.
Blood Cancer Journal|September 22, 2023
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneityTalha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, et al.
British Journal of Haematology|March 18, 2020
Characteristics of patients with myelodysplastic syndrome with balanced translocationsMaansi Joshi, Patricia Greipp, Colleen Ball, et al.
British Journal of Haematology|March 5, 2025
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndromeYael Kusne, Talha Badar, Terra Lasho, et al.
Leukemia Research|August 29, 2022
Comparison between GATA2 and DDX41-mutated myeloid neoplasmsAhmad Nanaa, Rong He, David Viswanatha, et al.
American Journal of Clinical Pathology|June 6, 2018
Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?Hong Fang, Prashant Kapoor, Wilson I Gonsalves, et al.
Transplantation and Cellular Therapy|May 18, 2025
Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell TransplantAnmol Baranwal, Christopher Graham, Khalil Hassan, et al.
Blood Advances|October 13, 2021
Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasmsHassan B Alkhateeb, Ahmad Nanaa, David Viswanatha, et al.
Blood Cancer Journal|April 9, 2023
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndromeAref Al-Kali, Ahmad Nanaa, David Viswanatha, et al.
Pageof 6